Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera®) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial

切碎 医学 美罗华 内科学 临床终点 淋巴瘤 胃肠病学 弥漫性大B细胞淋巴瘤 置信区间 CD20 随机对照试验
作者
Yuankai Shi,Qingyuan Zhang,Xiaonan Hong,Zhen Wang,Yuhuan Gao,Liqun Zou,Hong Cen,Lin Gui,Yufu Li,Jifeng Feng,Zhao Wang,Mingzhi Zhang,Chuan Jin,Weihua Zhang,Jianda Hu,Chengyun Zheng,Zhendong Zheng,Liling Zhang,Shaoshui Chen,Yunhong Huang
出处
期刊:Hematological Oncology [Wiley]
卷期号:40 (5): 930-940 被引量:5
标识
DOI:10.1002/hon.3054
摘要

This study compared the efficacy, safety and immunogenicity of ripertamab (SCT400) and rituximab (Mabthera® ) combined with CHOP as the first-line treatment for Chinese patients with CD20-positive diffuse large B cell lymphoma (DLBCL). This is a randomized, patient-blind, multicenter, active-control, non-inferiority study with parallel design. Patients were randomly (2:1) to receive ripertamab combined with CHOP (S-CHOP) or rituximab (Mabthera® ) combined with CHOP (R-CHOP) for up to 6 cycles. The primary endpoint was the Independent Review Committee (IRC) assessed objective response rate (ORR) in full analysis set (FAS) and the per protocol set (PPS). A total of 364 patients (243 in the S-CHOP and 121 in the R-CHOP groups) were enrolled in this study. In FAS, IRC-assessed ORRs were 93.8% (95% confidence interval (CI) 90.0%, 96.5%) and 94.2% (95% CI: 88.4%, 97.6%) in the S-CHOP and R-CHOP groups (p = 0.9633), respectively. The ORR difference between the two groups -0.4% (95% CI: -5.5%, 4.8%) met the pre-specified non-inferiority margin of -12%. There were no significant differences between the S-CHOP and R-CHOP groups in 1-year progression-free survival rates (81.1% vs. 83.2%, p = 0.8283), 1 year event-free survival rates (56.2% vs. 58.1%, p = 0.8005), and 3-year overall survival rates (81.0% vs. 82.8%, p = 0.7183). The results in PPS were consistent with those in FAS. The rates of treatment-emergent adverse events (TEAEs) and ≥ grade 3 TEAEs were 97.9% and 99.2%, 85.2% and 86.0% in the S-CHOP and R-CHOP groups, respectively in safety set. The percentage of anti-drug antibodies positive patients in the S-CHOP group was numerically lower than the R-CHOP group (10.9% vs. 16.0%). This study demonstrated that S-CHOP was not inferior to R-CHOP in the first-line treatment of Chinese patients with CD20-positive DLBCL in efficacy, safety and immunogenecity. S-CHOP could be an alternative first-line standard treatment regimen for this patient population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
1秒前
阿姨洗铁路完成签到 ,获得积分10
6秒前
抹不掉的记忆完成签到,获得积分10
8秒前
8秒前
余杭村王小虎完成签到,获得积分10
9秒前
韭黄完成签到,获得积分20
13秒前
jeffrey完成签到,获得积分10
13秒前
Rondab应助机灵枕头采纳,获得10
19秒前
佳无夜完成签到,获得积分10
24秒前
摆哥完成签到,获得积分10
28秒前
66完成签到,获得积分10
33秒前
zlqq完成签到 ,获得积分10
33秒前
Hardskills发布了新的文献求助10
36秒前
37秒前
之_ZH完成签到 ,获得积分10
45秒前
gds2021完成签到 ,获得积分10
47秒前
你好呀嘻嘻完成签到 ,获得积分10
47秒前
梅特卡夫完成签到,获得积分10
49秒前
熊雅完成签到,获得积分10
50秒前
52秒前
睡到自然醒完成签到 ,获得积分10
53秒前
cis2014完成签到,获得积分10
55秒前
独特的大有完成签到 ,获得积分10
55秒前
量子星尘发布了新的文献求助10
56秒前
58秒前
xingyi完成签到,获得积分10
1分钟前
1分钟前
舒心的秋荷完成签到 ,获得积分10
1分钟前
zz123发布了新的文献求助10
1分钟前
liaomr完成签到 ,获得积分10
1分钟前
粗犷的灵松完成签到,获得积分10
1分钟前
吃小孩的妖怪完成签到 ,获得积分10
1分钟前
ncuwzq完成签到,获得积分10
1分钟前
yshj完成签到 ,获得积分10
1分钟前
1分钟前
净禅完成签到 ,获得积分10
1分钟前
1分钟前
迷人的寒风完成签到,获得积分10
1分钟前
1分钟前
water应助科研通管家采纳,获得10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022